Aldeyra Secures US Orphan Drug Tag For Its Retinitis Pigmentosa Candidate

by Vandana Singh, Benzinga Editor
August 4, 2021 11:23 AM | 23 seconds read |
  • The FDA has granted orphan drug designation to Aldeyra Therapeutics Inc's ALDX ADX-2191 to treat retinitis pigmentosa (RP).
  • ADX-2191 is a methotrexate for intravitreal injection.
  • Methotrexate inhibits dihydrofolic reductase, an enzyme involved in cellular replication and activation.
  • Price Action: ALDX shares are up 0.56% at $9 during the market session on the last check Wednesday.
  • Related content: Benzinga's Full FDA Calendar.
Market News and Data brought to you by Benzinga APIs

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Comments
Posted In: BiotechNewsHealth CareSmall CapFDAGeneralBriefsOrphan Drug DesignationRetinitis Pigmentosa
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga

© 2024 Benzinga | All Rights Reserved